The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats

Basit Öğe Kaydı
dc.authoridParlakpinar, Hakan/0000-0001-9497-3468
dc.authoridAteş, Burhan/0000-0001-6080-229X
dc.authoridVardı, Nigar/0000-0003-0576-1696
dc.authoridOzhan, Onural/0000-0001-9018-7849
dc.authoridÇOLAK, CEMİL/0000-0001-5406-098X
dc.authoridParlakpınar, Hakan/0000-0001-9497-3468
dc.authorwosidParlakpinar, Hakan/V-6637-2019
dc.authorwosidAteş, Burhan/AAA-3730-2021
dc.authorwosidUlutaş, Zeynep/JMB-6092-2023
dc.authorwosidErmis, Necip/HJP-7061-2023
dc.authorwosidVardı, Nigar/C-9549-2018
dc.authorwosidOzhan, Onural/AAE-2356-2020
dc.authorwosidErmis, Necip/A-5184-2018
dc.contributor.authorUlutas, Zeynep
dc.contributor.authorErmis, Necip
dc.contributor.authorOzhan, Onural
dc.contributor.authorParlakpinar, Hakan
dc.contributor.authorVardi, Nigar
dc.contributor.authorAtes, Burhan
dc.contributor.authorColak, Cemil
dc.date.accessioned2024-08-04T20:48:44Z
dc.date.available2024-08-04T20:48:44Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThis study investigated the protective effects of Compound 21 (C21), the first specific non-peptide AT2 receptor agonist, on cardiac injury in rats with isoproterenol-induced heart failure in vivo and compared it with valsartan, an AT1 receptor antagonist. In this study, 56 Wistar albino male rats (estimated body weights 250-400 g) were divided into eight groups (n = 7). Group 1 (Control) received no drug. Group 2 (ISO) was given 180 mg/kg of isoproterenol subcutaneously (s.c.); two doses were administered at 24-h intervals on days 29 and 30 of the experiment. Groups 3, 4, and 5 were given valsartan (30 mg/kg orally), C21 (0.03 mg/kg intraperitoneally), and a combination of Valsartan + C21, respectively, for 30 days. Groups 6, 7, and 8 were administered Valsartan, C21, and Valsartan + C21 in the same application, duration, and dose, respectively, and isoproterenol (180 mg/kg s.c.) was given on days 29 and 30 of the experiment. Transthoracic echocardiography was performed on the rats at the beginning and end of the experiment. Blood pressure, heart rate, and ECG alterations were monitored via a carotid artery cannula at the end of the experiment. Histopathological and biochemical measurements were performed on the cardiac tissue of the rats. For histopathological findings, C21 and Valsartan + C21 combination therapy significantly reduced the development of heart failure compared to valsartan alone. Also, the protective effect of C21 on myocardial injury was superior to that of valsartan. According to the results of echocardiographic and biochemical evaluations, C21, and Valsartan showed protective effects against heart failure. C21, valsartan, and combined therapy significantly prevented the decrease of ejection fraction. This report describes the cardioprotective effects of C21 and valsartan in ISO-induced myocardial damage.en_US
dc.description.sponsorshipScientific Research Fund of Inonu University/Malatya/Turkey [2016/41]en_US
dc.description.sponsorshipThis study was supported by a Grant from The Scientific Research Fund of Inonu University/Malatya/Turkey (Project ID: 2016/41). The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: https://www.textcheck.com/certificate/qZgHHn.en_US
dc.identifier.doi10.1007/s12012-020-09590-6
dc.identifier.endpage28en_US
dc.identifier.issn1530-7905
dc.identifier.issn1559-0259
dc.identifier.issue1en_US
dc.identifier.pmid32648158en_US
dc.identifier.scopus2-s2.0-85087727579en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage17en_US
dc.identifier.urihttps://doi.org/10.1007/s12012-020-09590-6
dc.identifier.urihttps://hdl.handle.net/11616/99408
dc.identifier.volume21en_US
dc.identifier.wosWOS:000546904000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofCardiovascular Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAngiotensin IIen_US
dc.subjectCompound 21 (C21)en_US
dc.subjectHeart failure (HF)en_US
dc.subjectValsartanen_US
dc.titleThe Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu